ImmunOs Therapeutics
Latest round
- Series C
Last raised
- Sep 2024
Total raised
- $98M
Investors
- 14
About ImmunOs Therapeutics
ImmunOs Therapeutics AG, founded in 2014 in Zurich, Switzerland, focuses on the development of therapeutics aimed at enhancing immune responses.ImmunOs Therapeutics specializes in the development of biologic therapeutics that leverage a unique HLA-based technology platform.ImmunOs Therapeutics generates revenue primarily through partnerships with pharmaceutical companies and clinical trial collaborations, notably with Merck, emphasizing B2B transactions.
Who invested in ImmunOs Therapeutics
14 investors across 3 rounds
See all investors in ImmunOs Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ImmunOs Therapeutics
Who invested in ImmunOs Therapeutics?
ImmunOs Therapeutics has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmunOs Therapeutics raised?
ImmunOs Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ImmunOs Therapeutics last raise money?
ImmunOs Therapeutics's most recent round on record is a Series C, in Sep 2024.
What does ImmunOs Therapeutics do?
ImmunOs Therapeutics AG, founded in 2014 in Zurich, Switzerland, focuses on the development of therapeutics aimed at enhancing immune responses.
Where is ImmunOs Therapeutics headquartered?
ImmunOs Therapeutics is headquartered in Zurich, Switzerland.
Which VCs invest in companies like ImmunOs Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at ImmunOs Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like ImmunOs Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.